LFMGX
Price
$20.51
Change
-$0.82 (-3.84%)
Updated
Feb 21 closing price
Net Assets
188.16M
VEXRX
Price
$106.16
Change
-$3.05 (-2.79%)
Updated
Feb 21 closing price
Net Assets
22.89B
Ad is loading...

LFMGX vs VEXRX

Header iconLFMGX vs VEXRX Comparison
Open Charts LFMGX vs VEXRXBanner chart's image
Lord Abbett Micro Cap Growth F
Price$20.51
Change-$0.82 (-3.84%)
VolumeN/A
Net Assets188.16M
Vanguard Explorer Adm
Price$106.16
Change-$3.05 (-2.79%)
VolumeN/A
Net Assets22.89B
LFMGX vs VEXRX Comparison Chart
Loading...
View a ticker or compare two or three
VS
LFMGX vs. VEXRX commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFMGX is a StrongBuy and VEXRX is a Hold.

Ad is loading...
FUNDAMENTALS
Fundamentals
VEXRX has more cash in the bank: 22.9B vs. LFMGX (188M). VEXRX pays higher dividends than LFMGX: VEXRX (0.58) vs LFMGX (0.00). LFMGX was incepted earlier than VEXRX: LFMGX (4 years) vs VEXRX (23 years). LFMGX is a more actively managed with annual turnover of: 121.00 vs. VEXRX (40.00). LFMGX has a lower initial minimum investment than VEXRX: LFMGX (0) vs VEXRX (50000). LFMGX annual gain was more profitable for investors over the last year : 15.74 vs. VEXRX (0.68).
LFMGXVEXRXLFMGX / VEXRX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence4 years23 years-
Gain YTD-5.874-0.646910%
Front LoadN/AN/A-
Min. Initial Investment050000-
Min. Initial Investment IRAN/AN/A-
Net Assets188M22.9B1%
Annual Yield % from dividends0.000.58-
Returns for 1 year15.740.682,309%
Returns for 3 years13.193.31398%
Returns for 5 yearsN/A6.84-
Returns for 10 yearsN/A18.06-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QCRH76.58-0.09
-0.12%
QCR Holdings
VYGR4.22-0.04
-0.94%
Voyager Therapeutics
ADMA15.84-0.24
-1.49%
ADMA Biologics
IX99.90-1.78
-1.75%
ORIX Corp
ENLV1.00-0.02
-1.81%
Enlivex Therapeutics Ltd